Get access

Biology of Factor XIII and clinical manifestations of Factor XIII deficiency

Authors

  • Jerrold H. Levy,

    Corresponding author
    1. From the Emory University School of Medicine, Cardiothoracic Anesthesiology, and Critical Care Emory Healthcare, Atlanta, Georgia; and the Medical University of South Carolina, Hematology/Oncology, MUSC Hollings Cancer Center, Charleston, South Carolina.
      Jerrold H. Levy, MD, FAHA, Emory University School of Medicine, Cardiothoracic Anesthesiology and Critical Care, 1364 Clifton Road, NE, Atlanta, GA 30322; e-mail: jlevy01@emory.edu.
    Search for more papers by this author
  • Charles Greenberg

    1. From the Emory University School of Medicine, Cardiothoracic Anesthesiology, and Critical Care Emory Healthcare, Atlanta, Georgia; and the Medical University of South Carolina, Hematology/Oncology, MUSC Hollings Cancer Center, Charleston, South Carolina.
    Search for more papers by this author

Jerrold H. Levy, MD, FAHA, Emory University School of Medicine, Cardiothoracic Anesthesiology and Critical Care, 1364 Clifton Road, NE, Atlanta, GA 30322; e-mail: jlevy01@emory.edu.

Abstract

Factor XIII (FXIII) is activated by thrombin to form a transglutaminase (FXIIIa) that stabilizes clot formation by the cross-linking of fibrin monomers and antifibrinolytic proteins. Although rare, FXIII deficiency is characterized by variable bleeding manifestations depending on the magnitude of the deficiency. A congenital FXIII deficiency with levels less than 1% can be detected in children who present with prolonged bleeding from the umbilical stump as well as protracted bleeding after trauma. An acquired FXIII deficiency may occur in a number of diseases or clinical situations where FXIII levels and/or its activity are decreased. Patients may also develop a relative deficiency in FXIII as a result of hemorrhage or dilutional changes from transfusions during surgery or trauma and are at increased risk for postoperative bleeding. Genetic studies have identified a wide range of mutations that affect the activity of the FXIII protein but in lieu of molecular genetic analyses, FXIII deficiency can be identified by specific diagnostic assays that measure either the transglutaminase activity of the protein or the levels of the protein and its individual subunits. Replacement therapy has also been shown to increase FXIII levels and reduce bleeding symptoms in patients with congenital FXIII deficiency. This review presents recent findings on the biology of FXIII and the clinical manifestations observed among patients with congenital and acquired FXIII deficiencies.

Get access to the full text of this article

Ancillary